abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
91863: BRCAvantage™, Comprehensive Print View
Known Family BRCA Mutation      
Spec. Familial Mutation      
Spec. Familial Del/Dup      
Interpretation Summary      
BRCA1 Sequencing NGS     
BRCA1 Seq Interp      
BRCA1 Del/Dup MLPA     
BRCA1 Del/Dup Interp      
BRCA2 Sequencing NGS     
BRCA2 Seq Interp      
BRCA2 Del/Dup MLPA     
BRCA2 Del/Dup Interp      
Comprehensive Interp      
Additional Information      

PRIMARY
1 Whole Blood EDTA 4 (2) mL   Refrigerated - 8 Day(s)/Room Temperature - 8 Day(s)  
ALTERNATE

Hereditary breast cancer accounts for about 5% to 10% of female breast cancer and 4% to 40% of male breast cancer. The most common cause is mutations in the BRCA1 and BRCA2 genes. Mutations in these genes also account for up to 15% of all ovarian cancers. This test detects mutations through BRCA1 and BRCA2 sequencing as well as BRCA1 and BRCA2 deletion/duplication testing.

Whole Blood: Normal phlebotomy procedure; specimen stability is
crucial. Store and ship room temperature immediately. Do not
freeze. Send report of results for family member with known BRCA
mutation.
Setup Schedule
Tuesday, Thursday, Saturday

Reported (Analytical Time)
12 days

CPT Code
81162

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
Method: Next Gen Sequencing and Multiplex Ligation Primer Amplification (MLPA) Report available: 12 days from completed pre-authorization






© 1996 - 2017 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database